Ovid Therapeutics Inc. - Special Call Transcript
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Ovid Therapeutics Conference Call. (Operator Instructions) It is now my pleasure to turn the call over to Jeff Rona, Consulting CFO of Ovid Therapeutics. Please go ahead, sir.
Thank you, operator, and thank you, everyone, for dialing in today.
Earlier this morning, Ovid and Takeda announced positive top line results from the Phase II ELEKTRA trial of soticlestat in Dravet syndrome and Lennox-Gastaut syndrome. The press release can be found on Ovid's website at www.ovidrx.com. Please note that we will have a webcast slide to accompany this call. For those dialing in, it may be helpful to go to the Investors page of the Ovid website and access the webcast player now if you haven't done so already. A PDF of the webcast slides will also be made available.
Joining me on the call this morning are Dr. Jeremy Levin, Chairman and Chief Executive Officer of Ovid; and Dr.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
